P2i Extends Pipette Nano-Coating Range
News Sep 08, 2005
P2i Limited has announced the launch of its range of repellent nano-coatings to the international medical device and consumables sector at Stand 8M27 in ComPaMed, Dusseldorf from 16th -18th November.
The pipette tips utilise P2i proprietary cold plasma-enhanced chemical vapour deposition (PECVD) process to apply nano-thin coatings which dramatically enhance their performance, virtually eliminating liquid retention.
Extensive testing in P2i’s custom-built nano-coating chambers has shown that P2i-enhanced pipette tips produce accurate and reliable results.
The ultra-low adhesion, pin-hole free coating has a surface energy 3x lower than Teflon® (PTFE) and has no leachable components.
According to P2i, this advance offers major benefits across the full spectrum of pipetting applications – from handheld pipettes to large scale robotic liquid handling systems.
P2i’s CEO, Quentin Compton-Bishop, said, “With sample volumes getting smaller all the time in both research and routine medical applications, avoiding precious sample loss through surface retention becomes even more critical.”
“We are now looking to follow our success with pipette tips by applying nano-coatings to microplates, filters, textiles and other medical consumables. Visitors to our stand at ComPaMed will be able to see the potential for themselves. ”
Further he said, “Our process can be used to deposit a range of functional groups on both plastic and glass surfaces. For example, we can create hydrophilic surfaces and other specific reaction sites for proteins.”
P2i’s onsite facilities include 40-litre, 300-litre and 2000-litre chambers, supported by the expertise of its team of plasma process chemists.
Mr Compton-Bishop commented, “Our range of chambers can process single-use disposable products as small as frits and pipette tips in their thousands through to larger items such as whole medical devices and protective apparel. For high level users, however, we can install bespoke chambers at customer sites under licence.”